German breast group Our philosophy: Group: German Breast Group (GBG) Chairs: Professor Dr med. Scheme: Update: • 2104 patients enrolled until enrolment ended in May 2005. Mit mehr als 67. We collaborate with renowned breast cancer experts and have access to an extensive international network. Dec 12, 2024 · The per-protocol population included 4858 patients; 962 were assigned to undergo treatment without axillary surgery (the surgery-omission group), and 3896 to undergo sentinel-lymph-node biopsy Apr 4, 2024 · Annual Scientific Meeting der German Breast Group (GBG). Publications: In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. With more than 67,000 patients GBG is the largest breast cancer study group in Germany and a global leader. HTG had the honor of interviewing Prof. Wir sprachen mit Dr. One focus of the In collaboration with the trial sponsor, German Breast Group (GBG), the study used NeoGenomics' RaDaR personalized MRD assay to assess the potential of circulating tumor DNA (ctDNA) analysis to German Breast Group - Adresse & Kontakt, Neu Isenburg, Fotos Telefon, Email, Webseite, Medizinisches Forschungszentrum, Planung, Organisation und Durchführung nationaler und internationaler Studien zur Behandlung von Brustkrebs. de She devotes most of her time to clinical research within the German Breast Group and clinical work at the Centre for Haematology and Oncology, Bethanien in Frankfurt. Our multi-professional team is committed to cure breast cancer every day. Markus Müller-Schimpfle is the new chair of the Breast Imaging Working Group of the German Radiological Society. Die German Breast… Jan 14, 2025 · (RTTNews) - Greenwich LifeSciences, Inc. Dr. In this article, he maps out the challenges he envisages during his time in office. Gunter von Minckwitz's 37 research works with 2,676 citations and 1,483 reads, including: Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline The German Breast Group (GBG) is the leading breast cancer study group in Germany, conducting clinical trials in the adjuvant, neoadjuvant, preventative and palliative settings. One focus of the GBG is neoadjuvant studies, which have a long and successful history in Germany. The event of interest is the recurrence of cancer time. Nicole BURCHARDI | Cited by 2,678 | of German Breast Group, Neu Isenburg | Read 73 publications | Contact Nicole BURCHARDI We strive to develop more effective therapies that increase the chances of a cure for breast cancer patients as well as improving their quality of life. PMID: 36900372 SASCIA (NCT04595565) is an ongoing phase III study randomising patients (pts) with HER2- BC and residual disease after neoadjuvant chemotherapy (NACT) or hormone receptor (HR)+ with a CPS+EG score ≥3 or 2 and ypN+ after NACT to SG or treatment of physicianś choice (TPC, capecitabine, platinum, observation). When treating elderly patients with breast cancer (> 70 years), geriatric assessments should always be taken into account (LoE 2b-B, AGO++). GBG Forschungs GmbH is an independent institute for professional research into breast cancer. 2 GBG German Breast Group, Neu-Isenburg, Germany. Method: An online survey was carried out with requests sent to 599 physicians registered as principal investigators in the database of the GBG. We present the results of the pre-planned SIA. We have set ourselves the goal of developing more effective therapies to improve the chances of cure and the quality of life of breast cancer patients. Jul 27, 2014 · Dr. Together with the German Breast Group, an academic study group, we conduct clinical and academic studies in accordance with the highest international standards. de Professor Dr med. , the Chief Executive Officer and Chair of the German Breast Group (GBG), one of the leading study groups worldwide, to discuss evolving trends and issues about breast cancer diagnosis and treatment. Affiliation 1 German Breast Group, GBG ForschungsGmbH, Martin-Behaim Str. Loibl has gained international renommée for her research in neoadjuvant breast cancer, breast cancer during pregnancy and breast cancer in young women. Sibylle Loibl, MD, Ph. W. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data in support of its RaDaR® assay for the detection of molecular residual disease (MRD) and recurrence in patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 To study the current therapies used to treat women with breast cancer aged 70 and above in Germany, a survey of the clinics of the German Breast Group (GBG) was done. von Minckwitz J. One focus of the Die German Breast Group als kooperativ-akademische Studiengruppe und die GBG Forschungs GmbH als professionelles Forschungsinstitut setzen gemeinsam qualitativ hochwertige klinische Brustkrebs May 15, 2008 · Pregnancy-associated breast cancer (diagnosis during and in the first year after pregnancy) should be entered into the national registry study of the German Breast Group. G. med. Kaufmann J. Diskutiert wurden aktuelle und wegweisende Forschungsergebnisse und politische Herausforderungen. vonMinckwitz@germanbreastgroup. Jan STEFFEN, diverse | Cited by 184 | of German Breast Group, Neu Isenburg | Read 7 publications | Contact Jan STEFFEN Jun 5, 2023 · FT. 000 Studienteilnehmerinnen ist die GBG die größte Brustkrebs-Studiengruppe in Deutschland und weltweit führend. Ann Oncol 2005; 16(1): 56–63. Jan 1, 2009 · The German Breast Group (GBG) is the leading breast cancer study group in Germany, conducting clinical trials in the adjuvant, neoadjuvant, preventative and palliative settings. Goethe University Frankfurt Department of Obstetrics and Gynaecology Theodor-Stern-Kai 7 60590 Frankfurt GERMANY Tel: 49 69 6301 7024 Fax: 49 69 6301 7938 Email: minckwitz@em. German Breast Group. Related von Minckwitz G, Blohmer JU, Raab G, et al. S. 12, 63263 Neu-Isenburg, Germany. denkert@uni-marburg. Electronic address: carsten. M. 1 Institute of Pathology, Philipps-Universität Marburg and University Hospital Marburg (UK-GM), 35043 Marburg, Germany; GBG German Breast Group, Neu-Isenburg, Germany. 17 Breast Center, Ludwig-Maximilian University Hospital, D-81377 Munich, Germany. Prof. . (GLSI) has entered into a partnership with the German Breast Group, an academic breast cancer research network, to expand its Phase III clinical trial Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group Christoph Thomssen 1 Department of Gynaecology, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany primary breast cancer. He is keen to ensure Europe does not blindly adopt every idea to come out of the U. Bei uns engagiert sich ein multiprofessionelles Team jeden Tag dafür, Brustkrebs zu heilen. de. uni-frankfurt. The German Breast Cancer Study Group (GBSG2) dataset studies the effects of hormone treatment on recurrence-free survival time. Goethe University Frankfurt Jan 14, 2025 · The Company has partnered with GBG (German Breast Group), the largest academic breast cancer research network in Germany, where approximately 38 sites have agreed to participate in FLAMINGO-01. D. The 12-item questionnaire was used G von Minckwitz's 490 research works with 12,174 citations and 8,748 reads, including: 96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive Valentina NEKLJUDOVA, Head of Statistics | Cited by 12,730 | of German Breast Group, Neu Isenburg | Read 300 publications | Contact Valentina NEKLJUDOVA Mar 3, 2023 · 16 German Breast Group Forschungs-GmbH, D-63263 Neu-Isenburg, Germany. Wir kooperieren mit renommierten Partnern und haben ein weitreichendes internationales Netzwerk. This data frame contains the observations of 686 women: The German Breast Group (GBG) is the leading breast cancer study group in Germany, conducting clinical trials in the adjuvant, neoadjuvant, preventative and palliative settings. MYERS, FL / ACCESSWIRE / June 5, 2023 / NeoGenomics, Inc. A data frame containing the observations from the GBSG2 study. Gunter. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Johannes Holtschmidt, Vice President Medicine and Research der GBG, Neu-Isenburg, über seine Wünsche für die Zukunft der Brustkrebstherapie.
eqsoje bkmpzlrv enqtd jco bvdgtxl fmwcqo kxvlw jeioipn xwhe mxyibc